The Effects of Celecoxib on Bone Ingrowth

Early Phase 1TerminatedNCT00585156

University of Utah9 enrolled

Overview

The purpose of this study is to evaluate the effect of Celebrex on bone growth into porous coated implants, following postoperative total knee arthroplasty administration of Celebrex for pain relief.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Bone Ingrowth Pain

Interventions

CelecoxibDRUG

Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.

Eligibility

Sex: MALEMin age: 18 YearsMax age: 95 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male VA bilateral TKA patients 18 years or older with primary OA diagnosis Exclusion Criteria: * Patients with osteoporosis, hypersensitivity to Celebrex, allergy to tetracycline, Sulfonamides, patient with asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs. * Patients who have had CABG. * Patients with a history of peptic ulcer disease, duodenal ulcers. * Female patients and patients diagnosed with unstable hypertension or hypotensive, with serum creative levels above 1.8-2.0 or diagnosed with severe renal disease.

Locations (1)

Veteran Affairs (VA) Medical Center

Salt Lake City, Utah, United States

Outcomes

Primary Outcomes

Bone Ingrowth

Time frame: 12 weeks

Secondary Outcomes

Pain Score

Time frame: 10 days postoperative

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.